anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine, specifically to providing user authentication. Disclosed is a method involving transmission by an entity related to an institution that provides patient data and/or access to patient data, cloud system for supporting clinical decision making of a first request and a first session marker generated by an object and containing an identifier for identifying an interaction session of an object with a cloud-based system for supporting clinical decision making. First request relates to an action requiring object authentication and to be performed by a cloud-based clinical decision support system over de-identified data stored in a cloud-based system for supporting clinical decision making. Method comprises a step of obtaining on object a second request and a second session marker, comprising an identifier for identifying an interaction session of an object with a cloud-based clinical decision support system transmitted by a cloud-based clinical decision support system to said object. At that, the second request requests validation of the second session marker. Method includes a step of comparing first and second session markers on a comparison object. Method includes a step of generating a reliability signal on the object, indicating whether the first and second session markers match. Method includes a step of transmitting an object of a reliability signal to a cloud support system for making clinical decisions and obtaining an indication on the object that the cloud clinical decision support system has performed the requested action. Also disclosed is a system containing an object related to an institution that provides data on patients and/or accesses data on patients, and implemented with the possibility of implementing the method. Object comprises a computing device and a user authentication system; and a cloud-based clinical decision support system comprising an object authentication system. User authentication system and the object authentication system are configured to control the access of the object to the de-identified patient data stored in the cloud-based clinical decision support system.EFFECT: group of inventions provides higher efficiency of user authentication.10 cl, 4 dwg
REZLIDHIA can cause hepatotoxicity, presenting as increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), increased blood alkaline phosphatase, and/or elevated bilirubin. Of 153 patients with relapsed or refractory AML who received REZLIDHIA, hepatotoxicity occurred in 23% of patients; 13% experienced grade 3 or 4 hepatotoxicity [see Adverse Reactions (6.1)]. One patient treated with REZLIDHIA in combination with azacitidine in the clinical trial, a combination for which REZLIDHIA is not indicated, died from complications of drug-induced liver injury. The median time to onset of hepatotoxicity in patients with relapsed or refractory AML treated with REZLIDHIA was 1.2 months (range: 1 day to 17.5 months) after REZLIDHIA initiation, and the median time to resolution was 12 days (range: 1 day to 17 months). The most common hepatotoxicities were elevations of ALT, AST, blood alkaline phosphatase, and blood bilirubin.

Monitor patients frequently for clinical symptoms of hepatic dysfunction such as fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice. Obtain baseline liver function tests prior to initiation of REZLIDHIA, at least once weekly for the first two months, once every other week for the third month, once in the fourth month, and once every other month for the duration of therapy. If hepatic dysfunction occurs, withhold, reduce, or permanently discontinue REZLIDHIA based on recurrence/severity [see Dosage and Administration (2.3)].
Absorption and Distribution

In man, dicyclomine is rapidly absorbed after oral administration, reaching peak values within 60-90 minutes. Mean volume of distribution for a 20 mg oral dose is approximately 3.65 L/kg suggesting extensive distribution in tissues.

Elimination

The metabolism of dicyclomine was not studied. The principal route of excretion is via the urine (79.5% of the dose). Excretion also occurs in the feces, but to a lesser extent (8.4%). Mean half-life of plasma elimination in one study was determined to be approximately 1.8 hours when plasma concentrations were measured for 9 hours after a single dose. In subsequent studies, plasma concentrations were followed for up to 24 hours after a single dose, showing a secondary phase of elimination with a somewhat longer half-life.
1. A method for treatment of a platelet suspension comprising the following steps: (A) exposure of the suspension to radiation in a wavelength range of 400 to 750 nm in the presence of one or several photoactive substances which have one or several absorption maximal in the wavelength range, and (B) exposure of the suspension to radiation in a wavelength range of 270 to 320 nm, the energy input is 0.1 to 10 J/cm<2>, wherein steps (A) and (B) can be used in arbitrary order and/or overlapping in time, and in step (B) there is no photoactive substance present which has an absorption maximum in the wavelength range of the radiation according to step (B). 2. The method according to claim 1, characterised in that the photoactive substance is a phenothiazine dye. 3. The method according to claim 2, characterised in that thionine, methylene blue, toluidine blue and/or the azure dyes A, B and C are used as phenothiazine dyes. 4. The method according to one of claims 2 or 3, characterised in that the photoactive substance in step (A) is used in a concentration of 0.5 to 10 muM, preferably 0.5 to 5 muM. 5. The method according to one of the preceding claims, characterised in that the intensity of the radiation in step (B) is set such that the proliferation capability of T-lymphocytes contained in the platelet concentrates is reduced by at least 50 %, preferably by more than 75 %. 6. The method according to one of the preceding claims, characterised in that in step (B) the energy input is 0.1 to 10 J/cm<2>, preferably 0.5 to 3 J/cm<2>. 7. The method according to one of the preceding claims, characterised in that in step (B) the suspension is exposed to radiation in a wavelength range of 290 to 320 nm. 8. The method according to one of the preceding claims, characterised in that the platelet suspensions are platelet concentrates. 9. The method according to one of the preceding claims, characterised in that the platelet suspensions or platelet concentrates were obtained from blood donation or by platelet apheresis. 10. The method according to one of the preceding claims, characterised in that the treatment of the suspension in accordance with step (A) and/or step (B) takes place in plastic containers transparent to the appropriate radiation. 11. The method according to one of the preceding claims, characterised in that the treatment of the suspension in accordance with step (A) and/or step (B) takes place in a flow-through apparatus transparent to the appropriate radiation. 12. The method according to one of the preceding claims, characterised in that the virus concentration of the suspension is reduced by at least 5, preferably by at least 6 log10 steps. 13. A method for treatment of a platelet suspension comprising the following steps: (A) exposure of the suspension to radiation in a wavelength range of 400 to 750 nm in the presence of one or several photoactive substances which have one or several absorption maximal in the wavelength range, and (B) exposure of the suspension to radiation in a wavelength range of 270 to 320 nm, the energy input is 0.1 to 10 J/cm<2>, wherein steps (A) and (B) can be used in arbitrary order and/or overlapping in time.
The invention provides goose-source lactobacillus plantarum ER41( Lactobacillus plantarum  ER41) with a preservation number of CCTCC No: m2021932. The lactobacillus plantarum ER41 of the invention has the following technical effects: 1) can produce acid rapidly, the pH value of 8h is reduced to below 4.0, the lactic acid yield of 24h is 165.87mmol/L, the acid production is rapid, and the lactic acid production capacity is strong. 2) Has antibacterial effect on Escherichia coli, Staphylococcus aureus, Salmonella and Listeria. 3) Can more effectively adhere to the epithelial cells of the goose intestinal tract and colonize in the goose intestinal tract. 4) Can improve the villus height of jejunum, ileum and cecum, obviously reduce the crypt depth of the ileum and the cecum, obviously improve the villus crypt ratio of the cecum and promote the healthy development of intestinal mucosa. 5) Can improve the content of short-chain fatty acids such as acetic acid and propionic acid in intestinal tract, and promote intestinal health. 6) Can obviously reduce the abundance of pathogenic bacteria such as escherichia coli, shigella, enterococcus and the like, improve the abundance of lactobacillus and adjust intestinal flora.
The overall goal of this study is to evaluate lung, large vessel, and right ventricular glucose uptake rate using 18FDG PET and distribution of pulmonary perfusion using 13NN PET in patients with pulmonary hypertension before and after treatment with ambrisentan. The investigators propose a pilot study of patients with Group I PAH. The investigators plan to complete this pilot study with 5 patients (projected enrollment of 8 to allow for drop-out rate). Taken together, the studies above demonstrate that FDG-PET can be used to detect changes associated with PAH, and to monitor response to therapy. FDG-PET is a widely available technology, and is firmly established in the field of clinical oncology. Ambrisentan is an endothelin receptor antagonist that is FDA-approved to treat patients with pulmonary arterial hypertension. Patients will be eligible for participation in this study if they have already made a decision to start treatment with ambrisentan for pulmonary hypertension. The investigators propose a physiologic study of patients who will already have made a decision to start ambrisentan therapy. Participation in the study will not alter or affect participants decisions regarding treatment.

Prior human studies evaluating response to PH-specific therapies focused only on the right ventricle. Oikawa et al. looked at the RV uptake in patients with PH and evaluated them before and after treatment with epoprostenol. Fang and colleagues used FDG-SPECT evaluate FDG uptake in the RV of patients with IPAH and PH before and after treatment with sildenafil. Both of those studies used SUV (specific uptake variable). The investigators propose to focus on the lung and the RV uptake rate (Ki) in order to provide a more robust analysis of the metabolic changes that underlie the development of pulmonary hypertension both in the right ventricle and the lung parenchyma, and to study the response to ambrisentan with FDG-PET.
Patients aged between 18-90 years old with primary hyperparathyroidism. No intervention is provided.
Olfactory bulb (OB) microglia activation and inflammation can lead to olfactory dysfunction, which often occurs after an ischemic stroke. Inhibition of soluble epoxide hydrolase (sEH) attenuates neuroinflammation in brain injuries by reducing the degradation of anti-inflammatory epoxyeicosatrienoic acids. However, whether sEH inhibitors can ameliorate olfactory dysfunction after an ischemic stroke remains unknown. Ischemic brain injury and olfactory dysfunction were induced by middle cerebral artery occlusion (MCAO) in Wistar Kyoto rats. The rats were administered 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), a selective sEH inhibitor. Olfactory function, cerebral infarct volume, and the degree of degeneration, microglial polarization and neuroinflammation in OB were evaluated. Following treatment with AUDA, rats subjected to MCAO displayed mild cerebral infarction and OB degeneration, as well as better olfactory performance. In OB, AUDA triggered a modulation of microglial polarization toward the M2 anti-inflammatory type, reduction in proinflammatory mediators, and enhancement of the antioxidant process. The effectiveness of AUDA in terms of anti-inflammatory, neuroprotection and anti-oxidative properties suggests that it may have clinical therapeutic implication for ischemic stroke related olfactory dysfunction.
By 2030, 70 million Americans will be over the age of 65. Currently, 70% of older adults have periodontal disease, 20% have untreated tooth decay, and 1 in 4 older adults have lost some or all of their teeth. This poses a significant problem as mounting evidence demonstrates a link between oral disease and life-threatening diseases, including premature death. Gum disease is associated with systemic conditions such as cardiovascular disease, stroke, diabetes mellitus, chronic kidney disease, respiratory disorders, dementia and cancers. Moreover, numerous studies suggest that the number of teeth lost in adulthood is a predictor of premature death. Therefore, an individual's oral health and general health are tightly linked and good oral hygiene could be an easy means of preventing serious, life-threatening conditions in many older adults.

For many older adults, decreased manual dexterity, physical or mental impairment, income constraints, lack of dental insurance, all contribute to and exacerbate oral disease. A cost-effective, nontoxic and easy-to-take oral solution has been developed; PTx800 rapid dissolving lozenges. The investigators are evaluating PTx800 lozenge performance on gum health and ease of use in the older adult population who frequent community centers in the greater Cleveland, Ohio area. Efficacy assessment will be determined over the course of 6 weeks on participants with confirmed mild-to-moderate gingivitis. Endpoint measurements on gum health for PTx800 vs placebo control will be evaluated. Furthermore, the ease of use and receptivity to the PTx800 lozenges will be assessed in order to determine whether the PTx800 lozenges could be a viable candidate to supplement standard oral hygiene practices. A comparison in the change in oral health outcomes and dental pathogen burdens will be investigated in the 6-week study. As a part of the study design, a survey of this population will be conducted to understand perceptions, biases and habits as they relate to oral health, social and emotional well-being. The culmination of this work will impart a better understanding of, and facilitate appropriate actions to address, the oral health crisis in older adults. The ultimate goal of this study is to identify methods to improve the quality of life for this demographic.
Maternal mortality and vitamin A deficiency coexist in rural South Asia. In Nepal, weekly supplementation with vitamin A or beta-carotene during the child-bearing years reduced all-cause maternal mortality and, in night blind women, also infant mortality. The present trial is testing the efficacy of the same supplements from \~9 weeks' gestation to 12 weeks postpartum. The planned sample size is 68,000 pregnancies. It is being conducted in 19 rural unions, covering an area of \~750 sq km with a population of \~580,000 in Gaibandha and Southern Rangpur Districts in Northern Bangladesh. The study area was mapped as 596 "sectors" (unit of randomization), each comprising 200-275 households; \~135,000 houses were numerically addressed and, at the outset, 103,000 women were listed. Women are visited at home every 5 weeks by 596 trained female staff to detect pregnancy by a combination of menstrual history and urine testing. Newly married women are prospectively enlisted for pregnancy surveillance. Following informed consent urine-positive (pregnant) women detected during surveillance are enrolled to receive weekly a capsule containing 7000 retinol equivalents of preformed vitamin A, 42 mg of beta-carotene or placebo. Vital events are recorded weekly through 3 months postpartum. Trained interviewers conduct maternal nutritional and health and household socioeconomic assessments in the 1st trimester. At 3 months postpartum, interviewers assess both mother and infant for health and nutritional status, including apparent birth defects that are later physician-confirmed. An additional home health assessment occurs at 6 months post partum, and vital status is recorded for mother and infant at one year postpartum. A \~3% subsample of enrolled pregnant women participate in a substudy involving enhanced clinical, anthropometric, biochemical, body compositional, morbidity and interview-based assessment protocols in the 1st, 2nd and 3rd trimesters, and at 3 months post-partum. Reported maternal and infant deaths are verified and causes ascertained during "verbal autopsy" interviews with family members of the deceased.
PURPOSE: Perioperative decision making for large (> 2 cm) rectal polyps with ambiguous features is complex. The most common intraprocedural assessment is clinician judgement alone while radiological and endoscopic biopsy can provide periprocedural detail. Fluorescence-augmented machine learning (FA-ML) methods may optimise local treatment strategy.
METHODS: Surgeons of varying grades, all performing colonoscopies independently, were asked to visually judge endoscopic videos of large benign and early-stage malignant (potentially suitable for local excision) rectal lesions on an interactive video platform (Mindstamp) with results compared with and between final pathology, radiology and a novel FA-ML classifier. Statistical analyses of data used Fleiss Multi-rater Kappa scoring, Spearman Coefficient and Frequency tables.
RESULTS: Thirty-two surgeons judged 14 ambiguous polyp videos (7 benign, 7 malignant). In all cancers, initial endoscopic biopsy had yielded false-negative results. Five of each lesion type had had a pre-excision MRI with a 60% false-positive malignancy prediction in benign lesions and a 60% over-staging and 40% equivocal rate in cancers. Average clinical visual cancer judgement accuracy was 49% (with only 'fair' inter-rater agreement), many reporting uncertainty and higher reported decision confidence did not correspond to higher accuracy. This compared to 86% ML accuracy. Size was misjudged visually by a mean of 20% with polyp size underestimated in 4/6 and overestimated in 2/6. Subjective narratives regarding decision-making requested for 7/14 lesions revealed wide rationale variation between participants.
CONCLUSION: Current available clinical means of ambiguous rectal lesion assessment is suboptimal with wide inter-observer variation. Fluorescence based AI augmentation may advance this field via objective, explainable ML methods.
A solution of 30 g fructan in 200 mL of tap water will be infused once over a period of 20min. during 1 of the 3 investigation days.
OBJECTIVES: The gut-liver axis is discussed to play an important role in hepatic cirrhosis. Decompensated liver cirrhosis is associated with portal hypertension, which can lead to a variety of complications. Transjugular intrahepatic portosystemic shunt (TIPS) is an established treatment option for the complications of portal hypertension. In this study we focused on the effect of TIPS on intestinal microbial composition in cirrhotic patients.
METHODS: Thirty patients with liver cirrhosis were compared to 18 healthy adults. Seventeen patients with cirrhosis and portal hypertension received a TIPS. Clinical characteristics, including age, sex, and liver function measured with a Child-Pugh score and model for end-stage liver disease score, were obtained. Intestinal microbial composition was assessed via 16S rRNA gene amplicon sequencing from stool probes before and after TIPS.
RESULTS: TIPS led to a reduction of hepatic venous pressure gradient. However, TIPS did not cause a shift in the intestinal bacterial communities. Independent from the application of TIPS, antibiotic therapy was associated with a significant difference in the intestinal bacterial microbiota and also a reduced α-diversity. In addition, a significant difference was observed in the intestinal bacterial composition between patients with liver cirrhosis and healthy controls.
CONCLUSION: The presence of liver cirrhosis and the use of antibiotic therapy, but not the application of TIPS, were associated with a significant shift of the intestinal bacterial communities, showing a high impact on the microbiota of patients with liver cirrhosis.
The subjects will be treated with colistin monotherapy. Colistin (100 mg, colistin sodium methanesulfonate, SCD Pharm., Seoul, Korea) will be intravenously administered with 100 mL of normal saline with 8 hours interval. Treatment should be maintained daily administration for at least 7 days and up to 28 days. Duration of antibiotics treatment will be determined through discussion by pulmonology and infection specialist.
This research was designed as a pre-test-post-test randomized controlled experimental study. Nursing students from a university in Hangzhou, China served as the research subjects, who were randomly assigned to the experimental or control group. The control group received training in the regular course and was given compensatory intervention after the experiment, while the experimental group received intergroup contact training (the regular course combined with intergroup contact content). Such training was carried out in the forms of both individual and group interventions for a duration of 12 weeks. The levels of aging stereotypes, intergroup anxiety, and the willingness to engage in geriatric nursing among the nursing students were investigated before and after the training. Number, percentage, mean, standard deviation, Shapiro-Wilk, T-test, Wilcoxon signed ranks tests, and Mann-Whitney U tests were used to analyze the data.
Cold spray group injection process step; In addition to the IM injection procedure steps, Cryos cold spray was applied to patients in this group after skin cleansing. Cryos cold spray sprayed 3 puffs from a distance of 20 cm to the skin, and the injection process was performed. Within 2 minutes after the injection process was completed, the patient was allowed to mark the intensity of pain caused by the needle while entering the tissue on the VAS.
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins. Before initiating therapy with MOXATAG, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens. If an allergic reaction occurs, MOXATAG should be discontinued and appropriate therapy instituted.

Serious anaphylactic reactions require immediate emergency treatment with epinephrine. Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated.
Cohort of 50 participants who are healthy Sri Lankan volunteers Inclusion and exclusion criteria below Measure of arterial stiffness using pulse wave velocity technology Assessment of BMI, central and brachial blood pressure, arterial stiffness and 'arterial age' will be made and fed back to the patient. this information will be given in a 'results sheet' that the participant will be encouraged to give to their Gp for further treatments required.